Takeda Pharmaceutical (TAK) Fundamental Analysis: Revenue, Earnings & Valuation

7.55 / 10

Outperform

With a 7.5/10 fundamental rating, the stock demonstrates good characteristics. Strengths in Fixed assets turnover ratio and Cost of sales ratio (%), though challenges appear in Current ratio and PB-ROE. suggest superior potential.

Analysis Checks(8/10)

Total operating revenue (YoY growth rate %)

Value7.45

Score2/3

Weight3.60%

1M Return0.85%

PB-ROE

Value-0.69

Score1/3

Weight19.66%

1M Return4.50%

Income tax / Total profit (%)

Value38.23

Score3/3

Weight22.17%

1M Return4.49%

Fixed assets turnover ratio

Value2.32

Score2/3

Weight-1.94%

1M Return-0.48%

Interest coverage ratio (EBIT / Interest expense) (%)

Value2.07

Score2/3

Weight-3.25%

1M Return-0.82%

Operating revenue (YoY growth rate %)

Value7.45

Score2/3

Weight4.72%

1M Return1.10%

Cost of sales ratio (%)

Value34.49

Score3/3

Weight3.37%

1M Return0.74%

Asset-MV

Value1.34

Score3/3

Weight63.42%

1M Return10.58%

Inventory turnover days

Value276.48

Score2/3

Weight2.35%

1M Return0.56%

Current ratio

Value1.01

Score0/3

Weight-14.11%

1M Return-3.71%

Is TAK undervalued or overvalued?

TAK scores 7.55/10 on fundamentals and holds a Discounted valuation at present. Backed by its 2.96% ROE, 2.54% net margin, 78.23 P/E ratio, 1.21 P/B ratio, and -39.04% earnings growth, these metrics solidify its Outperform investment rating.